Acomplia and Alli are two anti-obesity drugs which are awaiting FDA approval
Two obesity reducing drugs are awaiting FDA approval and if approved could provide the pharmaceutical manufactures with high profits due to sales of these drugs. These new drugs are to be reviewed by the federal regulators before it could be available as a counter sales drug. Acomplia and Alli are the two new anti-obesity drugs and could help in weight loss management.
Acomplia is manufactured by Sanofi-Aventis and the drug acts by controlling the brain signals which triggers signals for controlling appetite and stimulation to eat more. Alli is produced by GlaxoSmithKline which acts by controlling the body’s fat absorption leading to weight loss, Alli is available in drug market under the trade name of xenical, which on clinical trials was found not to cause any adverse effects and was found to reduce 12.4 pounds of weight on an average six months of taking the drug.
